These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10874445)

  • 1. [The pharmacoeconomics of treatment of severe infections in intensive care].
    Zambrowski JJ
    Ann Fr Anesth Reanim; 2000 May; 19(5):430-5. PubMed ID: 10874445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacoeconomics of infection in the intensive care unit].
    Grau S; Alvarez-Lerma F
    Rev Esp Quimioter; 2008; 21 Spec No 1():26-34. PubMed ID: 18752077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibiotic pharmacoeconomics].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2008 Nov; 25(149):437-8. PubMed ID: 19177784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
    Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
    Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacoeconomics of acne treatment: where are we heading?
    Inglese MJ; Fleischer AB; Feldman SR; Balkrishnan R
    J Dermatolog Treat; 2008; 19(1):27-37. PubMed ID: 18273722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomics.
    Sule NS; Nerurkar RP; Kamath SA
    J Assoc Physicians India; 2002 Aug; 50():1057-62. PubMed ID: 12421032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational use of antibiotics in the intensive care unit: impact on microbial resistance and costs.
    Geissler A; Gerbeaux P; Granier I; Blanc P; Facon K; Durand-Gasselin J
    Intensive Care Med; 2003 Jan; 29(1):49-54. PubMed ID: 12528022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomics of appropriate antimicrobial use.
    Davey P
    Diagn Microbiol Infect Dis; 1995; 22(1-2):225-9. PubMed ID: 7587044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact and relevance of antibiotic resistance.
    French GL
    Adv Drug Deliv Rev; 2005 Jul; 57(10):1514-27. PubMed ID: 15978698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Can we afford the costs of progress in intensive care medicine? A plea for a candid debate].
    Boldt J
    Dtsch Med Wochenschr; 2004 Jan; 129(1-2):36-40. PubMed ID: 14703580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future pharmacoeconomic criteria for the treatment of infections.
    Milkovich G
    Int J Antimicrob Agents; 2009 Jul; 34 Suppl 1():S12-4. PubMed ID: 19560668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nondrug costs of therapy in acute care--are they important?
    Edbrooke DL; Bourne RS
    Crit Care; 2003 Dec; 7(6):420-1. PubMed ID: 14624680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma substitutes: strategies for use in intensive therapy to maintain a correct ratio between therapeutic efficacy and costs].
    Piacevoli Q; Caccamo F
    Minerva Anestesiol; 2001 Jun; 67(6):457-65. PubMed ID: 11533544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of Gram-negative resistance.
    Evans HL; Lefrak SN; Lyman J; Smith RL; Chong TW; McElearney ST; Schulman AR; Hughes MG; Raymond DP; Pruett TL; Sawyer RG
    Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacoeconomical analysis of antibiotic use at the Clinic For Infectious Diseases of the Clinical Center of Vojvodina].
    Stefan-Mikić S; Jovanović J; Jovanović N; Sević S; Vukadinov J; Miucin-Vukadinović I
    Med Pregl; 2008; 61 Suppl 1():40-9. PubMed ID: 19248639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.